![Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5c60ab73-00a4-4f20-a6fd-72a7d2dff65d/jcpt12616-fig-0004-m.png)
Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/45b7403a-f302-4d9b-8970-ff2f69279ecf/jcpt12616-fig-0002-m.jpg)
Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - ScienceDirect Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1569199318307951-gr3.jpg)
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - ScienceDirect
![Journal of Cystic Fibrosis | Abstracts of the 40th European Cystic Fibrosis Conference | ScienceDirect.com by Elsevier Journal of Cystic Fibrosis | Abstracts of the 40th European Cystic Fibrosis Conference | ScienceDirect.com by Elsevier](https://ars.els-cdn.com/content/image/1-s2.0-S1569199317X00027-cov200h.gif)
Journal of Cystic Fibrosis | Abstracts of the 40th European Cystic Fibrosis Conference | ScienceDirect.com by Elsevier
![Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/56a7ddcc-2e00-47c0-8e0f-a50345cfd562/jcpt12616-fig-0003-m.png)